Cargando…
Erratum. SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management. Diabetes Care 2018;41:1543–1556
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Diabetes Association
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6754234/ https://www.ncbi.nlm.nih.gov/pubmed/31431451 http://dx.doi.org/10.2337/dc19-er10a |
| _version_ | 1783453047152705536 |
|---|---|
| author | van Baar, Michaël J.B. van Ruiten, Charlotte C. Muskiet, Marcel H.A. van Bloemendaal, Liselotte IJzerman, Richard G. van Raalte, Daniël H. |
| author_facet | van Baar, Michaël J.B. van Ruiten, Charlotte C. Muskiet, Marcel H.A. van Bloemendaal, Liselotte IJzerman, Richard G. van Raalte, Daniël H. |
| author_sort | van Baar, Michaël J.B. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-6754234 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2019 |
| publisher | American Diabetes Association |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-67542342019-10-04 Erratum. SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management. Diabetes Care 2018;41:1543–1556 van Baar, Michaël J.B. van Ruiten, Charlotte C. Muskiet, Marcel H.A. van Bloemendaal, Liselotte IJzerman, Richard G. van Raalte, Daniël H. Diabetes Care Errata American Diabetes Association 2019-10 2019-08-20 /pmc/articles/PMC6754234/ /pubmed/31431451 http://dx.doi.org/10.2337/dc19-er10a Text en © 2019 by the American Diabetes Association. http://www.diabetesjournals.org/content/licenseReaders may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license. |
| spellingShingle | Errata van Baar, Michaël J.B. van Ruiten, Charlotte C. Muskiet, Marcel H.A. van Bloemendaal, Liselotte IJzerman, Richard G. van Raalte, Daniël H. Erratum. SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management. Diabetes Care 2018;41:1543–1556 |
| title | Erratum. SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management. Diabetes Care 2018;41:1543–1556 |
| title_full | Erratum. SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management. Diabetes Care 2018;41:1543–1556 |
| title_fullStr | Erratum. SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management. Diabetes Care 2018;41:1543–1556 |
| title_full_unstemmed | Erratum. SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management. Diabetes Care 2018;41:1543–1556 |
| title_short | Erratum. SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management. Diabetes Care 2018;41:1543–1556 |
| title_sort | erratum. sglt2 inhibitors in combination therapy: from mechanisms to clinical considerations in type 2 diabetes management. diabetes care 2018;41:1543–1556 |
| topic | Errata |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6754234/ https://www.ncbi.nlm.nih.gov/pubmed/31431451 http://dx.doi.org/10.2337/dc19-er10a |
| work_keys_str_mv | AT vanbaarmichaeljb erratumsglt2inhibitorsincombinationtherapyfrommechanismstoclinicalconsiderationsintype2diabetesmanagementdiabetescare20184115431556 AT vanruitencharlottec erratumsglt2inhibitorsincombinationtherapyfrommechanismstoclinicalconsiderationsintype2diabetesmanagementdiabetescare20184115431556 AT muskietmarcelha erratumsglt2inhibitorsincombinationtherapyfrommechanismstoclinicalconsiderationsintype2diabetesmanagementdiabetescare20184115431556 AT vanbloemendaalliselotte erratumsglt2inhibitorsincombinationtherapyfrommechanismstoclinicalconsiderationsintype2diabetesmanagementdiabetescare20184115431556 AT ijzermanrichardg erratumsglt2inhibitorsincombinationtherapyfrommechanismstoclinicalconsiderationsintype2diabetesmanagementdiabetescare20184115431556 AT vanraaltedanielh erratumsglt2inhibitorsincombinationtherapyfrommechanismstoclinicalconsiderationsintype2diabetesmanagementdiabetescare20184115431556 |